Clearpoint Neuro Inc
clearpointneuro.comWhat Do They Do?
Sells minimally invasive neurosurgical navigation and therapy systems, intracranial fluid-management devices, and brain drug-delivery tools to hospitals, physicians, and pharmaceutical companies.
10-K for FY2025, filed Mar 17, 2026Our primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components…View ↗
In 2025, through the acquisition of IRRAS, we added the IRRAflow Active Fluid Exchange System (the “IRRAflow system”) to our portfolio of…View ↗
The second component of our business is focused on partnerships in the biologics and drug delivery space, supporting our customers from the…View ↗
How Do They Make Money?
Customers buy disposable devices and equipment; product sales are counted when items ship or are delivered, with installation required for some systems. Customers also buy consultation and development work, with revenue earned as services are delivered.
10-K for FY2025, filed Mar 17, 2026Neurosurgery navigation, therapy, neurocritical care, and biologics and drug delivery product sales: Revenue from the sale of neurosurgery…View ↗
Capital equipment and software sales preceded by evaluation periods: Revenue for capital equipment and software sales (consisting of…View ↗
Capital equipment and software sales not preceded by evaluation periods: Revenue from sales of capital equipment and software not having…View ↗
Consultation and Development Services: The Company recognizes consultation and development service revenue over time as the services are…View ↗
-
10-K for FY2025, filed Mar 17, 2026
FY2025 revenue by product or service ↗
$37M
-
10-K for FY2025, filed Mar 17, 2026
$37M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue
Sold outright
10-K for FY2025, filed Mar 17, 2026 |
65%
FY2022: 62%
|
Product revenue, FY2025
$23.9M Sources
|
Sold outright |
|
Service and other revenue
Recurring
10-K for FY2025, filed Mar 17, 2026 |
35%
FY2022: 38%
|
Service and other revenue, FY2025
$13.1M Sources
|
Recurring |
Who Are Their Customers?
Hospitals and physicians are marketed to directly for neurosurgery and neurocritical-care devices; pharmaceutical and other medical technology companies are approached directly for drug-delivery products and services. The company also works with academic and contract research organization partners.
10-K for FY2025, filed Mar 17, 2026physicians who care for patients suffering from neurological disorders, including stereotactic or functional neurosurgeons, who perform the…View ↗
With the acquisition of IRRAS, we have expanded our commercial reach into the neurocritical care and acute intracranial fluid management…View ↗
Commercializing our ClearPoint products and services for biologics and drug delivery primarily involves marketing and selling directly to…View ↗
As of March 6, 2026, we had commercial relationships with over 60 pharma/biotech, academic, and contract research organization partners who…View ↗
10-K for FY2025, filed Mar 17, 2026
One pharmaceutical customer, a related party that is a former stockholder and former noteholder, and whose chief executive officer is a…View ↗
Do Revenues Turn Into Profits?
No. It lost $25.5M in FY2025.
10-K for FY2025, filed Mar 17, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 3, 2026
−$11.3MView ↗
- ▲ +94% (Loss)
- vs −$5.8M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 3, 2026
Open tableView ↗
-
Aug 3, 2026
Lowers revenue outlook and announces focused-ultrasound partnership
The company adjusted its 2026 revenue guidance to between $48.0 - $52.0 million and announced a 10-year SONOCARE Lab partnership.
Sources
8-K, filed Aug 3, 2026
“As we embrace this new and important market information, our revised 2026 priorities are designed to build capacity across the full…View ↗
-
May 21, 2026
Appoints R. John Fletcher board chairman
Sources
8-K, filed May 21, 2026
The Board also confirmed the appointment of Mr. Fletcher as Chairman of the Board.View ↗
Growing. Revenue grew 2.3x in 4 years, from $16.3M in FY2021 to $37M in FY2025, about 23% a year.
Neurocritical care
The portfolio expanded into neurocritical care with an intracranial fluid-management system, alongside the earlier neurosurgical navigation and brain drug-delivery businesses.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Mar 17, 2026
Operating-room procedures
The latest business description adds end-to-end operating-room procedures, beyond the earlier system's operating-room placement and MRI completion.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Mar 17, 2026Our ClearPoint system is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software.…View ↗
Our primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components…View ↗
Broader research services
Services have broadened from pharmaceutical consulting to preclinical study design and execution, drug-safety research, and clinical-trial support.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Mar 17, 2026We are a commercial-stage medical device company, incorporated in 1998 as a Delaware corporation, that develops and commercializes…View ↗
Who Do They Compete With?
Competes with Monteris Medical, Medtronic, Brainlab, Elekta, FHC, Integra LifeSciences, Neurologica, Zimmer Biomet, Spiegelberg, Sophysa, B. Braun, and Renishaw
10-K for FY2025, filed Mar 17, 2026Currently, we are aware of two companies, Monteris Medical, Inc. and Medtronic, which offer devices for laser ablation under direct MRI…View ↗
Loading...
